MMP2 and melanoma: Conclusively, this study indicates that MMP-2 plays a role in Adriamycin resistance in melanoma mediated by p-ERK1/2 and thus targeting MMP-2/ERK1/2 may be a new targeted therapy for melanoma patients [109].